Results 191 to 200 of about 333,009 (323)

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Spatially Resolved 2D Laser Writing on Graphene Using Diazonium Salts. [PDF]

Chemistry
Krüger J, Nagel T, Yang B, Hauke F, Hirsch A.   +4 more
europepmc   +1 more source

Human agency, historical inevitability and moral culpability: Rewriting black-white history in the wake of Native Title

, 2011
Shayne Breen
openalex   +1 more source

Datatype defining rewrite systems for naturals and integers

, 2021
J.A. Bergstra, Alban Ponse
openalex   +1 more source

Multi‐Omics Integration for Advancing Glioma Precision Medicine

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Gliomas are among the most malignant and aggressive tumors of the central nervous system, characterized by the absence of early diagnostic markers, poor prognosis, and a lack of effective treatments. Advances in high‐throughput technologies have facilitated a refined molecular classification of gliomas, incorporating genetic features. However,
Maria Guarnaccia, Valentina La Cognata, Giulia Gentile, Giovanna Morello, Sebastiano Cavallaro   +4 more
wiley   +1 more source

Rewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision. [PDF]

NPJ Breast Cancer
Habibi M, Haffty BG, Formenti SC.
europepmc   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Tackling copyright issues in AI image generation through originality estimation and genericization. [PDF]

Sci Rep
Chiba-Okabe H, Su WJ.
europepmc   +1 more source

Termination of Graph and Term Graph Rewriting

, 2016
Barbara König
openalex   +1 more source

Combining Rewriting and Incremental Materialisation Maintenance for Datalog Programs with Equality [PDF]

, 2015
Boris Motik, Yavor Nenov, Robert Piro, Ian Horrocks   +3 more
openalex   +1 more source